Thomas Garner, Executive Vice President, Chief Commercial Officer at Acadia Pharmaceuticals Inc.. Biography, career history and compensation sourced from SEC proxy filings.
About
Thomas Garner has served as ACADIA's Executive Vice President and Chief Commercial Officer since December 2024, overseeing global commercial strategy for DAYBUE and NUPLAZID. He brings more than 25 years of pharmaceutical commercial experience. Before joining ACADIA he was Senior Vice President and Chief Commercial Officer at Lexicon Pharmaceuticals (2023-2024) and spent over 20 years at Bristol Myers Squibb, most recently as Senior Vice President and head of the U.S. Cardiovascular and Established Brands business unit and earlier as U.S. brand lead for Camzyos (mavacamten). He holds a BSc (Honors) from the Royal Agricultural University and a General Management certification from INSEAD.
Roles
Acadia Pharmaceuticals Inc.
Executive Vice President, Chief Commercial Officer · Current role
December 2024–present
ACADIA Pharmaceuticals
Executive Vice President and Chief Commercial Officer
December 2024 - present
Lexicon Pharmaceuticals, Inc.
Senior Vice President and Chief Commercial Officer
October 2023 - 2024
Bristol Myers Squibb
Senior Vice President, Head of U.S. Cardiovascular and Established Brands
August 2022 - October 2023
Bristol Myers Squibb
Vice President and U.S. Brand Lead, Camzyos (mavacamten)
November 2020 - August 2022
Bristol Myers Squibb
Commercial leadership roles (20+ years)
2002 - 2022
Eli Lilly and Company / Boehringer Ingelheim
Commercial roles
—
Fixed Compensation
FY 2025
Salary
$525,000
ComponentAnnual base salary earned in FY2025
All other compensation
$32,773
Component401(k) match, insurance premiums, and other perquisites
Total compensation
$857,023
Performance Compensation
Data from FY 2025
Cash incentive
Non-equity incentive plan compensation
$299,250
Target Opportunity
—
PlanAnnual cash bonus under the corporate incentive plan